To the full analysis
Buyback calculator for Aurobindo Pharma
Aurobindo Pharma stock: key metrics
AUROPHARMA.NSAurobindo Pharma had an operating margin of 15.1% and a return on invested capital (ROIC) of 10.2% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 40.6% | 11.8% | 9.5% |
| 2008 | 41.6% | 13.8% | 9.8% |
| 2009 | 46.8% | 5.7% | 3.3% |
| 2010 | 55.4% | 22.9% | 15.7% |
| 2011 | 48.8% | 18.8% | 12.9% |
| 2012 | 16.8% | 9.6% | −2.7% |
| 2013 | 37.5% | 12.6% | 5.0% |
| 2014 | 53.2% | 39.1% | 13.0% |
| 2015 | 53.2% | 39.1% | 13.0% |
| 2016 | 55.4% | 40.8% | 14.7% |
| 2017 | 56.8% | 40.8% | 15.4% |
| 2018 | 57.9% | 40.2% | 14.7% |
| 2019 | 54.2% | 35.7% | 12.1% |
| 2020 | 56.6% | 38.0% | 12.3% |
| 2021 | 58.9% | 38.0% | 21.5% |
| 2022 | 55.4% | 33.3% | 11.3% |
| 2023 | 53.2% | 32.6% | 7.8% |
| 2024 | 55.2% | 36.0% | 10.9% |
| 2025 | 57.5% | 37.8% | 11.0% |
| 2026 | 39.2% | 15.1% | 10.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 22.7% | 10.3% | 5.7% |
| 2008 | 21.2% | 10.7% | 6.6% |
| 2009 | 8.1% | 4.0% | 2.4% |
| 2010 | 30.7% | 16.5% | 11.7% |
| 2011 | 23.0% | 13.7% | 9.6% |
| 2012 | −5.3% | 6.8% | −2.0% |
| 2013 | 11.3% | 10.3% | 4.0% |
| 2014 | 42.0% | 52.1% | 16.6% |
| 2015 | 30.6% | 41.7% | 12.2% |
| 2016 | 28.7% | 40.6% | 12.7% |
| 2017 | 24.6% | 38.9% | 14.2% |
| 2018 | 20.7% | 36.1% | 11.5% |
| 2019 | 17.0% | 31.3% | 8.9% |
| 2020 | 16.9% | 34.3% | 9.8% |
| 2021 | 24.3% | 32.9% | 15.8% |
| 2022 | 10.8% | 27.3% | 7.8% |
| 2023 | 7.2% | 24.3% | 4.8% |
| 2024 | 10.6% | 27.0% | 7.0% |
| 2025 | 10.7% | 26.3% | 7.0% |
| 2026 | 9.2% | 10.2% | 6.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.